Resultados de la búsqueda 501-510 of 6384 for Receptor

  1. Oncología (médica) - Ensayos clínicos

    Scottsdale/Phoenix, Ariz. The purpose of this study is tol compare the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy ...

  2. Oncología (médica) - Ensayos clínicos

    Scottsdale/Phoenix, Ariz. The purpose of this study is tol compare the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy ...

  3. Programa de tumores cerebrales - Ensayos clínicos

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  4. Oncología (médica) - Ensayos clínicos

    A Study of Cell, Serum, and Bone Marrow Bank for Patients receiving Chimeric Antigen Receptor T Cell Therapy for the Treatment of Cancer. Rochester, Minn ...

  5. Oncología (médica) - Ensayos clínicos

    Scottsdale/Phoenix, Ariz. The purpose of this study is tol compare the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy ...

  6. Oncología (médica) - Ensayos clínicos

    This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast ...

  7. Oncología (médica) - Ensayos clínicos

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  8. Oncología (médica) - Ensayos clínicos

    Scottsdale/Phoenix, Ariz. The purpose of this study is tol compare the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy ...

  9. Neurocirugía - Ensayos clínicos

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements ...